Musings from The Power List: Miguel Forte
Scientific progress alone isn't enough, says Miguel Forte, who argues that reimbursement and patient access will shape the next decade of cell and gene therapy
False
Advertisement
Related Content
Cell & Gene
Drug Discovery
Development & Clinical
Musings from The Power List: Miguel Forte
September 8, 2026
4 min read
Scientific progress alone isn't enough, says Miguel Forte, who argues that reimbursement and patient access will shape the next decade of cell and gene therapy
Small Molecules
Development & Clinical
Small Molecules
Musings from The Power List: Peng Lu
September 4, 2026
2 min read
Peng Lu argues that small molecules remain indispensable as AI transforms drug development
Future of Pharma
Future of Pharma
Business & Trends
What Will Drug Development Look Like in 2036?
September 3, 2026
7 min read
Members of The Medicine Maker’s 2026 Power List predict how AI, new modalities, integrated data, and shifting global markets will reshape the industry
Biopharma
Biopharma
Regulation & Standards
China’s Biopharma Homecoming
September 1, 2026
7 min read
Chinese biopharma leaders are returning from the West to build a more confident – and innovative – global industry, says Cyagen’s Lance Han